New drug extends survival for men with advanced prostate Cancer

for men with advanced hormone-resistant prostate cancer who have failed also chemotherapy, the new drug Zytiga (abiraterone acetate) with the steroid prednisone appears to boost survival, researchers report.

Based on current clinical trial data, Zytiga has been approved by the Food and Drug Administration in April. It works by inhibiting the production of the hormone male testosterone, that promotes the growth of cancer cells. In this regard, the drug mimics the hormone therapy.

Zytiga "extends overall survival in this patient population which had very limited treatment options after chemotherapy" researcher principal Dr. Fred Saad, Chief of Urology at the hospital Notre-Dame de Montréal, said at a press conference of Monday morning.

The men in the combination of drugs had a mean survival of 14.8 months, compared to 10.9 months for men taking placebo.

"Abiraterone represents an option of valuable treatment for patients with metastatic castration [hormone] - resistant of the prostate which had been previously treated with chemotherapy, very easy to manage, treatment-related toxicity in" Saad said.

The study was published in issue 26 May of the New England Journal of Medicine. The findings were also presented may 16 at the annual meeting of the American Urological Association, in Washington, D.C.

The study focused on the 1,195 men prostate cancer that has not responded to hormone therapy and that he had no prior chemotherapy. Researchers, hospitals of 147 in 13 countries, randomly men to take Zytiga more prednisone or placebo.

The combination of drugs was well tolerated and has given rise within fatigue, back pain and spinal compression taking men, compared to placebo, Saad said.

The most common side effects in people taking prednisone and Zytiga were lower white blood cell, a retention, rates of low potassium, abnormal liver function tests, blood pressure and heart problems, the researchers noted.

A one month supply 120 pills of Zytiga costs $ 5,000, said Kelly McLaughlin, a spokesman of Centocor Ortho Biotech Inc., manufacturer of the drug and a promoter of the study.

"This study tells us that there is a form of hormonal treatment, abiraterone, who works among people who had chemotherapy and hormonal treatment standard," said expert Dr. Anthony D'Amico of prostate cancer, head of the apparatus Genitourinary Oncology at Brigham and women's Hospital in Boston.

"It will provide people with the disease late with an opportunity for a prolonged survival that they had not before." "I can't say that it is a term of home because it is only a few months improved,", he added.

Aggressive prostate cancer may be able to make its own testosterone, cancer cells need to grow. "Zytiga blocks that", said D'Amico.

"This drug offers longer life and better quality of life in men with very advanced prostate cancer," said D'Amico. "There are studies now to see if this medication will improve the rate of healing in men with advanced, but not [metastatic cancer that has spread to other organs], prostate cancer,", he added.

Prostate Cancer studies find advantage in daily acetaminophen and walks Brisk

POP a Tylenol and take a brisk walk for protection against prostate cancer? This is what the results of two new studies published this week suggested.

In the first study, published Monday in the journal Cancer Epidemiology, biomarkers and prevention, scientists have found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing cancer of the prostatecompared with men. In addition, daily acetaminophen has been associated with an of 51% reduced risk of developing an aggressive form of the disease. The men who took acetaminophen for less than five years saw no protective benefit.

Previous research has shown that taking aspirin or other drugs anti-inflammatory drugs (NSAIDs) every day can reduce the risk of prostate cancer. The authors believe that the same may be true of acetaminophen; While not an NSAID, it has anti-inflammatory properties.

For the study, researchers looked at data 78,485 men who participated in the longitudinal Cancer Prevention study II Nutrition cohort, answering questions on the use of food and pharmaceutical plan every two years from 1992. During the period of follow-up, there were 8,092 cases of prostate cancer - much less in the group who took acetaminophen daily for five years.

The second study, published Tuesday online research on Cancer, involved 1,455 men who had already been achieved in prostate cancer stage. Researchers at the University of California, San Francisco (UCSF) and Harvard School of Public Health, then the men from 2004 to 2009 and found that those who engaged in regular brisk walking after diagnosis were significantly less likely to see their progression of the disease.

Men who walked fast - at a rate of approximately 3 miles per hour or faster - at least three hours per week were 57% less likely to experience of the progression of the disease (including high levels of PSA)(, secondary treatment of bone metastases and prostate cancer-related deaths), compared with men who walked less and more slowly.

"The important point is the intensity of activity," Erin Richman, a postdoctoral fellow at UCSF, said in a statement. "The March must be rapid for men to experience an advantage."

Researchers have said that the effect of speed walking remains independent of age, diagnosis, type of treatment and characteristics of the disease. Average age of patients at diagnosis was 65. The findings are consistent with previous research, which suggests that physical activity can help reduce the risk of deaths from the disease in some cases of prostate cancer.

Why the association? Reports MedPage Today:

Richman and his colleagues have noted that brisk walking may reduce resistance to insulin, which reduces bioavailable,-1 (IGF1) insulin-like growth factor and increases adiponectin levels, which are all associated with the decrease in the risk of prostate cancer advanced or fatal in vitro and in vivo.

Another potential source of reduction is inflammation reduced due to low circulation of Interleukin-6, high levels of which "predicts risk of 73% increased to die of cancer of the prostate in men of normal weight."wrote the researchers.

Prostate cancer is the second leading cause of cancer death in men. According to the National Cancer Institute, men about 32,050 die of cancer of the prostate in 2010 and 217,000 new cases were diagnosed. More than 2.2 million of men to the United States with prostate cancer.

Optimistic rock on Avastin in cancer of the ovary

ZURICH - Roche Holding AG, the world leader in Oncology medicines, struck an optimistic tone about the Outlook of its key Avastin drug approval in ovarian cancer prior to a meeting important industry next month.

Head of pharma group that Pascal Soriot told journalists Thursday he was confident Avastin will win European approval and it was also relatively optimistic for win U.S. drug support.

"In Europe... we are confident because generally in Europe you can get approval on the basis of data of good progression-free survival," Soriot said.

"In the United States, we still wait until the data are fully mature to see what the overall survival data are similar and get a good sense of the FDA response, but I must say that we have seen so far... we made relatively optimistic that we have a good chance at the United States.". Thus, "he says.

Application for Avastin, used to treat a range of tumours, has fallen over recent quarters after the drug was struck by the movements of the two sides of the Atlantic health authorities to limit its use in breast cancer.

Roche now rely on the use of the vendor of billions of dollars to treat cancer of the ovary to stimulate growth future sales and intends to submit for the approval of the United States, later this year once he gave overall survival. She has already filed for approval in Europe.

"We will demonstrate that avastin has an essential role to play in cancer of the ovary," Soriot said before the Conference of the American Society of Clinical Oncology (ASCO) earlier this month next to Chicago.

"Overall superb new data showing our pipeline progresses." We hope that the shift in the perception of Avastin, "Soriot said, referring also data on lung and skin cancer drugs that will be presented at the ASCO."

OPPORTUNITY BUSINESS

Roche will present data impact on MetMAb of lung cancer and was to produce this treatment for approval in 2014, Soriot said, adding that Roche also sought to develop the drug in other diseases such as breast cancer.

Doctors and investors will be also eyes studies on vemurafenib, a drug to treat the deadliest form of skin cancer.

Soriot, said the business opportunity of vemurafenib has been limited to the skin cancer metastatic because the smaller number of patients in this parameter, but there is more potential sales if it were to be developed in the adjuvant.

The Group has yet to decide on setting prices of treatment and has therefore not yet a peak estimate sales for it.

Drug of rock, which develops with private holding Plexxikon and ipilimumab, an experimental drug developed by the US group Bristol - Myers Squibb, are giving hope to patients who already had a few treatment options.

Soriot said there was a place for both agents and it looks vemurafenib as the first line of treatment in patients who are positive BRAF.

"Ipilimumab is a different officer." It is a compound based on the immune system to treat cancer. It is a drug which can potentially be given to all patients, while vemurafenib can only be given to patients who are positive BRAF, which is approximately 50% of patients with cancer melanoma, "Soriot said."

"It is important to keep in mind that the percentage of patients who respond really well to ipilimumab is relatively limited." These patients have a strong response, but it is a small percentage, probably 10 per cent of the patients, who meet, "he says.

Skin Cancer foes declared may 27 "Don't fry day" (HealthDay)

on Friday, the beginning of the end of week Memorial Day, is also "Don ' T fry day," once for skin safety experts remind Americans about the dangers of overexposure to the Sun.

Melanoma, the potentially deadly form of skin cancer is the most common cancer in young adults in the late twenties, according to the U.S. Environmental Protection Agency (EPA) and the National Council for the prevention of Skin Cancerwho have joined forces to offer advice to save lives on the caution in the Sun. The main cause of skin cancer: overexposure to harmful ultraviolet (UV).

"Many people still don't realize that exposure to the Sun without protection can lead to cancer of the skin and other health problems," said Gina McCarthy, agency Administrator assistant for the EPA Office of Air and radiation, in a press release. "Simple steps, such as using a sunscreen, wear sunglasses or a hat, can protect us and our families, while still enjoying the outdoors."

Skin cancer, the most common type of cancer in the United States, affects more than 2 million U.S. dollars - every year more breast cancer, prostate, lung and colon combined, said the EPA. Every hour, an American dies of cancer of the skin, the Agency noted.

Although the UV rays are dangerous year round, the risks are greatest in the summer months when people spend more time outdoors, McCarthy said.

To limit exposure to harmful UV rays, expert proposes to you:

Cover you. One of the most effective ways to reduce the exposure to the harmful rays of the Sun is to wear a shirt, hat and sunglasses and Sunscreen SPF 15 +. Find a shady place. It is best to stay out of direct light from the Sun during peak hours, from 10 h to 16 h being aware of the UV index. Get involved in outdoor activities, check the UV index to identify the time more risky for overexposure to the Sun.

Skin Cancer foes declared may 27 "Don't fry day"

on Friday, the beginning of the end of week Memorial Day, is also "Don ' T fry day," once for skin safety experts remind Americans about the dangers of overexposure to the Sun.

Melanoma, the potentially deadly form of skin cancer is the most common cancer in young adults in the late twenties, according to the U.S. Environmental Protection Agency (EPA) and the National Council for the prevention of Skin Cancerwho have joined forces to offer advice to save lives on the caution in the Sun. The main cause of skin cancer: overexposure to harmful ultraviolet (UV).

"Many people still don't realize that exposure to the Sun without protection can lead to cancer of the skin and other health problems," said Gina McCarthy, agency Administrator assistant for the EPA Office of Air and radiation, in a press release. "Simple steps, such as using a sunscreen, wear sunglasses or a hat, can protect us and our families, while still enjoying the outdoors."

Skin cancer, the most common type of cancer in the United States, affects more than 2 million U.S. dollars - every year more breast cancer, prostate, lung and colon combined, said the EPA. Every hour, an American dies of cancer of the skin, the Agency noted.

Although the UV rays are dangerous year round, the risks are greatest in the summer months when people spend more time outdoors, McCarthy said.

To limit exposure to harmful UV rays, expert proposes to you:

Cover you. One of the most effective ways to reduce the exposure to the harmful rays of the Sun is to wear a shirt, hat and sunglasses and Sunscreen SPF 15 +. Find a shady place. It is best to stay out of direct light from the Sun during peak hours, from 10 h to 16 h being aware of the UV index. Get involved in outdoor activities, check the UV index to identify the time more risky for overexposure to the Sun.

Women with high insurance subject to stop cancer drugs

 women taking breast cancer drugs are more likely to skip days or abandon processing entirely if their coinsurance is high, American researchers have found.

There is nothing new that people will often take the medicine that prescribes their doctor, but for cancer drugs, the consequences could be disastrous, experts say.

"Here we are talking about a drug to save lives,", said Dr. Alfred Neugut of Columbia University Medical Center in New York, whose results appear in the Journal of Clinical Oncology.

"Drugs are that important, perhaps that we put in place mechanisms to provide the means to circumvent the insurance or franchises."

Some insurance companies already have programs in place to ensure lower insurance for certain drugs, Neugut said, but they do cover inhibitor of aromatase, the focus of the new study.

These drugs, including Arimidex (AstraZeneca), significantly reduce the risk of death in cancer survivors who have been through menopause.

Arimidex can now be purchased as a generic drug for only less than a dollar by the pill, drug cost more than $2,000 per year when the study has been completed.

Neugut and colleagues used data from claims of MedCo Health Solutions to find out what role co-insurance patients could play or not, they took drugs for the recommended five years.

More 8 000 women aged 50 to 65, 20 percent stopped the drug at the beginning if their coinsurance was less than $30.

However, if the payment was $90 or more, 23 percent dropped drugs in advance.

For older women, the gap was five almost percentage, which Neugut chalks less available income.

There are similar differences in the number of women who jumped at least 20 per cent of the days, and the gap remained the same after researchers have considered possible explanations such as income and other factors.

"If the co-insurance gets too high, it will prevent people from taking a drug they really need," said Neugut, adding that previous research has noted the same effect for orders as a whole.

With health reform, more people should be covered by Medicaid, which means that they will have lower co-insurance. Neugut said that it is unclear what effect which were, in view of the beneficiaries of Medicaid but have fewer resources first.

He said that the problem is more serious for medicines against cancer than for other drugs, because the former deals with a potential fatal disease.

In addition, cancer drugs have side effects, which may also discourage women from taking them.

In General, Neugut told Reuters Health, "less than 50 per cent of women actually complete the five years - and if you do not, you lose most or all of the benefit of therapy."

Cancer Patients benefit from full access to medical records

Cancer Patients who are given full access to their medical record feel a greater sense of satisfaction about their treatment, a new study finds.

French researchers also concluded that provide complete and accurate medical information built of trust between the patient and the physician.

Published online on May 23 in the journal Cancer, the study analyzed 295 patients recently diagnosed cancer Lymphoma, breast or colon cancer. All were treated by chemotherapy.

Patients received either "on request information", or organized medical file (OMR) - a Briefcase complete detailed information on their condition and treatment. These information included reports on all, surgery, radiology and pathology results, with the nurse stories and observations of treatment. With SEO, they received guides on medical terms and understand the material, as well as to help medical personnel to decipher the various documents.

Eighty Eighteen per cent of patients who offered an OMR has chosen to take.

Patients who have received on-demand information has been provided only information and medical records if they asked for them or their doctor offered.

Similar anxiety and quality of life scores levels have been reported in the two groups.

But patients with OMR were 1.68 times more likely to be satisfied with their medical information and were 1.86 times more likely to feel fully informed, the authors of the study noted.

And 70.4% of the patients who received an OMR has said that they would once more to receive, with 74.8% saying: they not regret their choice. In addition, the majority of these patients has been reported that SEO was not the source of any anxiety.

"Information is crucial to make decisions of treatment options, and for the patient and his family, to cope with the disease and its consequences," study author Dr. Gwenaelle Gravis, the Paoli-Calmettes Institute in Marseillesaid in a press release of the editor of the journal. "Full access to his medical file with the possibility to consult only if you want increased patient confidence in the physician and the medical team."

Regular Brisk walking can protect patients with Cancer of the Prostate

Prostate cancer Patients who take great walks on a regular basis succeeds better than those who think the contrary, a new study suggests.

They not only reduce their risk of disease progression, they lower their chances of dying of the disease, researchers reported.

The conclusion is based on previous research in the same group of scientists who had indicated that "vigorous physical activity" reduces the risk of dying from prostate cancer.

"Men who participate in walking fast, defined as three miles per hour or faster, after clinically localized prostate cancer diagnosis had a reduction of the risk of progression of prostate cancer than men who walked to an easy pace less than two miles per hour"study author Erin said"" L. Richman, research associate in the Department of epidemiology and biostatistics at the University of California, San Francisco.

"Men who engaged in three hours per week or more brisk walking has had the greatest advantage", Richman added, "with a lower risk of 57% of the progression of the disease compared to men having come less than three hours per week at an easy pace." These results were independent clinical prognostic factors, dietary factors and factors of life such as obesity and smoking. ?

Report of the Richman appears in number 1 June of Cancer Research.

The authors of the study noted that about 2.2 million men are now struggling with a diagnosis of prostate cancer in the United States, and the disease is the second leading cause of cancer death in American men. In 2010, approximately 217,000 new cases were diagnosed.

To explore how lifestyle can influence the progression of the disease after a diagnosis, the study team focused on 1,455 patients with prostate cancer who were enrolled in one of the 40 Clinical Urology in 2004 and 2005.

At the time where the study launched, all men had localized cancer, which means that their disease had not yet spread beyond the prostate.

All the men completed a survey to assess their physical activity routines. Richman notes that most of the men had initially suffered "cure," including the radical treatment of prostactectomy or radiation.

The researchers found that walking represents approximately half of all physical activity exercised by patients, and that those that have been observed walking in so-called "deep" way tended to be younger and more appropriate than those who walked more slowly. Brisk walkers were also less likely to smoke.

By stacking patterns of exercise against signs of telltale of progression of the disease (such as the PSA levels, the spread of the disease or death), the research team found that patients who walked quickly for a minimum of three hours per week had a rate of progression of the disease (57 per cent below) significantly lesser than those who walked at an easy pace for less than three hours per week.

In fact, the pace of the March appeared to be more important than the amount of time spent walking. Walk at an easy pace conferred no advantage of protection against the progression of prostate cancer.

The team of the informed Richman that additional research is needed to confirm the results. She also suggested that other types of exercise may also be useful.

Mr. Lionel l. Banez, Assistant Professor in the division of Urologic Surgery, in the Department of surgery at Duke University Medical Center has agreed that further research might find that other forms of exercise provide similar protection.

"It's very reasonable to extrapolate these findings to include other forms of physical activity", he noted. "Our own previous study show that moderate exercise which included various forms of physical activity, has been associated with less aggressive prostate cancer risk in veterans."

Most cancer patients, such as full access to files

NEW YORK - Cancer patients who were given full access to their medical records at the beginning of the said treatment records helped to understand and discuss their disease with others, and they were not more concerned than other patients in a new study of the France.

There was a tendency to improve patient access to their own health information, some physicians fear that give full records patients will increase their anxiety, the authors note in the journal Cancer.

But Dave deBronkart, a prominent blogger on the participation of the patient since his own recovery from advanced kidney cancer, argues that full access is useful.

deBronkart, who blogs as "e-patient Dave", told Reuters Health via e-mail, "detailed information on the disease are important for the patient to make informed decisions." It also allows the patient and his family to cope better. ?

Participants in the new study included approximately 300 patients who had been recently diagnosed with cancer of the breast, cancer of the colon and lymphoma and started chemotherapy treatment.

Dr. Gwenaelle Gravis of the Paoli-Calmettes Institute in Marseille and colleagues randomly these patients in both groups.

In a group, patients received information in the usual manner for their institution - doctors could give patients their medical records if they chose, and patients may ask to see records on their own. In the other group, all patients who have accepted received their full medical records in a Briefcase with a user guide and were said to carry the Briefcase appointments so that records could be continuously updated.

In the beginning, middle and the end of the treatment, the researchers asked patients about their level of anxiety. Also, they gave participants a survey on quality of life and has asked on their understanding of their disease and treatment experience.

Anxiety levels were not different between the groups at any time during the treatment, and patients in both groups have also reported a quality of life like at the beginning and the end of chemotherapy.

Well that more than patients who received their full medical records saying that they were completely satisfied with the information they received and feel fully informed, this trend was not passed statistical tests to show a difference between groups.

The majority of patients who have received their complete medical record, said that the records helped to understand their disease in more detail and discuss with family members and physicians.

About 70 per cent of them said that if they had the choice to go back, they would receive their full file again.

Some patients complained that Briefcase with their records was too heavy to carry, or that its color was"inadequate", and a few others, has stated that they had insufficient information, or that it is difficult to organize the information that was there.

Gravis and his colleagues noted that giving patients a full access to their medical records could help foster confidence in their doctors in the long term, and it was easy to do.

deBronkart says he is "sick of people being in the institution, regardless of what say patients we want, think it is in our own interest if they make that decision for us."

"There is evidence that the majority of patients with cancer would like to receive as much information as possible", he added.

The authors cautioned that most of the patients had stage cancer with a good prognosis, and the results may not apply to patients of different types of cancer.

Peter Schmidt, Chief Information Officer at the National Foundation of Parkinson, who was not involved in the study, said it may also be useful for patients to have access to an "Adviser to medical records", because some files may have confusion of information.

Researchers have said that a study is needed on the responses of patients to access medical documented in other situations and circumstances - including in the context of electronic medical records, which could allow easy patientsconfidential access to the House.

They concluded that in this study at least, "allowing full access to the folders medical personal satisfaction increased without increasing anxiety in patients with newly diagnosed cancer.".

First person: sleep apnea, will appear and Cancer

CBS reported that a new study connects with cancer sleep apnea. People with sleep apnea have interrupted breathing during sleep periods. The study shows that disturbed respiration can spread cancer. I have sleep apnea and use a machine of spontaneous breathing.

A study in mice shows that cancerous tumours grow faster in those with sleep apnea. The sleep apnea has been linked to heart problems, also. When the breathing stops, it can damage the heart. Heart rate and breathing slowly during the night, but in people with sleep apnea, also known as Obstructive sleep apnea or OSA, breathing stops completely.

The sleep apnea is characterized by the deep, heavy snoring. The rest is pock-marked with stop-start episodes in which they partially wake blows to catch his breath. The severity of the sleep apnea is measured by the number of separations of respiration, called "apnea". Breathing is restarted with an involuntary intake of breath. Babies and children with infant sleep apnea always restart their own breathing. The infant sleep apnea is particularly dangerous.

To get adequate rest, a person must move through the full cycle of sleep. In the first stage, sleep is the light and the sleeper is easily awake. In step 2, sleep becomes more deep and slow brain waves. Three stage is characterized by sleep deep and slow brain waves of delta.

The last step is REM (rapid eye movement). Sleepdex describes REM in this way: "breathing becomes more rapid, irregular and little deep, eyes quickly jerk and limb muscles are temporarily paralyzed. Brain waves this stage increase to levels experienced when a person is awake. Also, increased heart rate, blood pressure increases... "It is at a time when most dreams occur and, if awake during REM sleep, a person may remember dreams."

Normal adults spend 50 percent of sleep in scene two, 20 percent in REM and 30% in other cycles. Because people with sleep apnea are constantly restarting their breathing patterns, their sleep cycles are disturbed.

I was diagnosed with apnea sleep in 2009. My sleep studies revealed that I spent only five percent of my sleep in the sleep of step 2 or 3 deep. For each hour of sleep, I was getting only about five to ten minutes of actual rest. I buzzer and experienced constant intense dreams. I had a lot of apnea every night and often woke up feeling that I strangle me.

I started with a machine of spontaneous breathing (continuous Positive airway pressure). Since I have questions to allergy and sinus I breathe through my nose. My CPAP mask covers my mouth and nose. I also have a deviated septum which causes respiratory problems. In 2010, I had a septoplasty with turbinate reduction surgery to correct deviated septum.

Before surgery and using CPAP, I would fall asleep at the wheel, speak and interact with people. I could be in bed for 11 hours and always be exhausted. I couldn't do more than four hours without falling asleep. I have had frequent back pain, headaches and muscle problems. I was in constant pain. I took Paxil for depression.

Between the CPAP and septoplasty, I am now much better sleep. I wake up refreshed and not fall asleep all the time. I am less pain. I have stopped since taking Paxil and is no longer the depression experience. People told me that they hate their CPAP. I could not sleep without mine. If the sleep apnea cancer spreads and causes heart problems, it may have saved my life.

Marilisa Kinney Sachteleben wrote 22 years, parents of four children, K - 8, special needs, adult education and home-school for 25 years.

Film star Australian Bill Hunter died of cancer at 71 (AP)

CANBERRA, Australia - being the epitome of a working class Australian with a distinctive focus of wide and gravel face worn by weather and a no-nonsense kept Bill Hunter style application as a player until the end.

He got his break in 1959 when legends Hollywood film "On the Beach" in his hometown of Melbourne.

Hunter appeared in the quirky trio "Muriel's wedding," "The adventures of Priscilla, Queen of the desert" and "" strictly Ballroom. "" He found his audience younger as the voice of dentist that has captured the star of clownfish of the functionality of 2003 animated hit "Of Nemo."

More recently, narrated a documentary on the Australia natural disasters this year and he has two upcoming films.

The prolific star of cinema and Australian television screens died of cancer late Saturday in a hospice of Melbourne, surrounded by family and friends, said his manager Mark Morrissey. Hunter was 71. Colleagues who had recently worked with him were surprised that he had been ill.

"Bill was very appreciated, a gentleman, a source of inspiration for other actors, a companion and a thief," Morrissey said.

Director Baz Luhrmann described Hunter in a statement last week as "go - to iconic actor to synthesize the quintessential Australian-ness."

Correspondent of the BBC Sydney Nick Bryan wrote in 2008 that "Hunter is to Australian films what the Ravens at the Tower of London." Without his presence rondelet, these films would be doomed to fall. ?

Prime Minister Julia Gillard tribute Sunday to a national icon who played a key role in the definition of Australian culture on five decades on screen and the stage.

Face before the weather of the Hunter has become almost ubiquitous on Australian screens since it appeared as a supplement in 1957 in "the shiralee", a film by British manufacturing in Australia.

His real break came as a stuntman in Hollywood "On the Beach" in Melbourne. The film on the survivors of a nuclear war with Gregory Peck, Ava Gardner and Fred Astaire.

"He looked Gregory Peck do 27 takes and thought:"a mug could do this,""ex-wife of Hunter Rhoda Roberts said The Daily Telegraph of Sydney newspaper last week."."

Hunter summarized his own approach to acting in a recent interview to promote his upcoming film of racing, "the cup".

"As long as the Director told me to do and what to say, I was happy." Someone who says there is no more to what is full of (expletive), "Hunter said in a quote published Sunday by his manager."

The Australia National Film and Sound Archive of film programming Chief Quentin Turnour said that Hunter followed in the tradition of Australian actors non-polished Chips Rafferty, who died in 1971, and John Meillon, died in 1989. The Australian public liked to see in the terse and gruff characters with soft hearts they played, said Turnour.

"It is so iconographiquement Australian." It transforms gestures Australian typical, minimalist in a lot of emotional expression, "said Turnour.

Hunter was born on February 27, 1940 and grew up in the State of rural Victoria in South-East of the Australia. He was the son of the owner of a pub in countries that have difficulties which finally ruined. Hunter told the newspaper The Sunday Age of Melbourne in 1994 that he left school at the age of 13 to become a cowboy, known in Australia as a drover, directors of herds of cattle Victoria.

He began to build his career in the 1960s in the dramas of crime of Australian television in which he specialized as a hard character who were generally of the police or criminals.

A herd with a knack attaching hard drinker of recalling the names of the people who expected to be forgotten, Hunter was universally popular in the film industry in which it became a pillar with a few peers.

A career highlight came when he played a cameraman news filmed in Phillip Noyce directed film on media and politics in Australia in the 1950s, "newsfront." Hunter has won awards from the Australian Film industry to 1978 for the role, the first of three such Australian equivalent of an Oscar he earned.

He has also won acclaim for his roles as an army for the failure of major in the drama of war 1981 Peter Weir "Gallipoli," a Justice of the dancing interference in the comedy of romantic 1992 Luhrmann "Strictly Ballroom," father of the bride in P.J. Hogan "Muriel wedding" and an engineer in the company of drag queens openness to Stephan Elliott "Priscilla."

Two comedy "Muriel wedding" and "Priscilla" have been made at the same time in 1994 in different regions of the Australia and required Hunter to have different lengths, a beard one hair and shaved close in the otherthe Internet Movie Database, said.

Hunter also had minor roles in the epic of 2008 of the "Australia" Luhrmann and co-production of miniseries for Australian television U.S. "The Pacific" was released last year.

Hunter recently narrated a documentary on floods and cyclone which were more expensive natural disasters of the Australia this year. He plays the racehorse Australian legendary trainer Bart Cummings and a role of cameo in two movies to be tested later this year.

"red dog," a family film based on a true story Outback, appears in some Australian cinemas in August. "The Cup" is scheduled to be released in Australia in October.

The PSA test earlier Best predicts the risk of dying of Prostate Cancer: study (HealthDay)

Researchers analyzed blood samples 12,090 between 1974 and 1986 Swedish men, whereas they were ages 44 to 50, samples of nearly 5,000 men, six years later, when they were aged 51 to 55 and samples of 1,167 men who were 60.

The men with PSA levels below the median, whereas they were 44-50 had a very low risk of death by cancer of the prostate or metastasis in 15 years. At the age of 60 years, these men with PSA levels below the median, the risk of prostate cancer had significantly decreased to 0.5%.

Although the current American Cancer Society guidelines suggest all but men at high risk should discuss screening with their doctor at the age of 50 years, the study authors say that their results indicate earlier tests could reduce unnecessary testing later.

The results indicate that more than half of men may waive regular PSA Test after this period and were just three tests PSA in their lives, with the first aged 44 to 50, the second between 51 and 55 years, and - if their PSA levels still low is - the third and last 60 years, said researchers at Memorial Sloan - Kettering Cancer Center in New York.

However, men with higher levels of PSA between the ages of 44 and 50 are high aggressive prostate cancer risk and should continue to undergo screening and APS as necessary, researchers have added.

The study to be presented to journalists today 18 may at the annual meeting of the American Society of Clinical Oncology.

"This research helps us to distinguish between men who can benefit from regular PSA for cancer of the prostate and the men who cannot be screening need not so often," lead author Dr. Hans Liljaa clinical chemist with appointments in the departments of medicine, laboratoireChirurgie and medicine, said in a press release of the Memorial Sloan-Kettering.

"Instead of testing all men efforts every year or every two years, screening and surveillance can concentrate on the early detection of cancer of the prostate in men who are considered at high risk of dying from the disease.".

PSA testing is recommended for the early detection of prostate cancer, but is associated with a high rate of over-diagnosis and excessive treatment, which is a concern because the treatment of cancer of the prostate can lead to erectile and urinary problems debilitating.

Because the study is presented at a medical meeting, its results should be considered preliminary until published in a refereed journal.

Film star Australian Bill Hunter died of cancer at 71 (AP)

CANBERRA, Australia - being the epitome of a working class Australian with a distinctive focus of wide and gravel face worn by weather and a no-nonsense kept Bill Hunter style application as a player until the end.

He got his break in 1959 when legends Hollywood film "On the Beach" in his hometown of Melbourne.

Hunter appeared in the quirky trio "Muriel's wedding," "The adventures of Priscilla, Queen of the desert" and "" strictly Ballroom. "" He found his audience younger as the voice of dentist that has captured the star of clownfish of the functionality of 2003 animated hit "Of Nemo."

More recently, narrated a documentary on the Australia natural disasters this year and he has two upcoming films.

The prolific star of cinema and Australian television screens died of cancer late Saturday in a hospice of Melbourne, surrounded by family and friends, said his manager Mark Morrissey. Hunter was 71. Colleagues who had recently worked with him were surprised that he had been ill.

"Bill was very appreciated, a gentleman, a source of inspiration for other actors, a companion and a thief," Morrissey said.

Director Baz Luhrmann described Hunter in a statement last week as "go - to iconic actor to synthesize the quintessential Australian-ness."

Correspondent of the BBC Sydney Nick Bryan wrote in 2008 that "Hunter is to Australian films what the Ravens at the Tower of London." Without his presence rondelet, these films would be doomed to fall. ?

Prime Minister Julia Gillard tribute Sunday to a national icon who played a key role in the definition of Australian culture on five decades on screen and the stage.

Face before the weather of the Hunter has become almost ubiquitous on Australian screens since it appeared as a supplement in 1957 in "the shiralee", a film by British manufacturing in Australia.

His real break came as a stuntman in Hollywood "On the Beach" in Melbourne. The film on the survivors of a nuclear war with Gregory Peck, Ava Gardner and Fred Astaire.

"He looked Gregory Peck do 27 takes and thought:"a mug could do this,""ex-wife of Hunter Rhoda Roberts said The Daily Telegraph of Sydney newspaper last week."."

Hunter summarized his own approach to acting in a recent interview to promote his upcoming film of racing, "the cup".

"As long as the Director told me to do and what to say, I was happy." Someone who says there is no more to what is full of (expletive), "Hunter said in a quote published Sunday by his manager."

The Australia National Film and Sound Archive of film programming Chief Quentin Turnour said that Hunter followed in the tradition of Australian actors non-polished Chips Rafferty, who died in 1971, and John Meillon, died in 1989. The Australian public liked to see in the terse and gruff characters with soft hearts they played, said Turnour.

"It is so iconographiquement Australian." It transforms gestures Australian typical, minimalist in a lot of emotional expression, "said Turnour.

Hunter was born on February 27, 1940 and grew up in the State of rural Victoria in South-East of the Australia. He was the son of the owner of a pub in countries that have difficulties which finally ruined. Hunter told the newspaper The Sunday Age of Melbourne in 1994 that he left school at the age of 13 to become a cowboy, known in Australia as a drover, directors of herds of cattle Victoria.

He began to build his career in the 1960s in the dramas of crime of Australian television in which he specialized as a hard character who were generally of the police or criminals.

A herd with a knack attaching hard drinker of recalling the names of the people who expected to be forgotten, Hunter was universally popular in the film industry in which it became a pillar with a few peers.

A career highlight came when he played a cameraman news filmed in Phillip Noyce directed film on media and politics in Australia in the 1950s, "newsfront." Hunter has won awards from the Australian Film industry to 1978 for the role, the first of three such Australian equivalent of an Oscar he earned.

He has also won acclaim for his roles as an army for the failure of major in the drama of war 1981 Peter Weir "Gallipoli," a Justice of the dancing interference in the comedy of romantic 1992 Luhrmann "Strictly Ballroom," father of the bride in P.J. Hogan "Muriel wedding" and an engineer in the company of drag queens openness to Stephan Elliott "Priscilla."

Two comedy "Muriel wedding" and "Priscilla" have been made at the same time in 1994 in different regions of the Australia and required Hunter to have different lengths, a beard one hair and shaved close in the otherthe Internet Movie Database, said.

Hunter also had minor roles in the epic of 2008 of the "Australia" Luhrmann and co-production of miniseries for Australian television U.S. "The Pacific" was released last year.

Hunter recently narrated a documentary on floods and cyclone which were more expensive natural disasters of the Australia this year. He plays the racehorse Australian legendary trainer Bart Cummings and a role of cameo in two movies to be tested later this year.

"red dog," a family film based on a true story Outback, appears in some Australian cinemas in August. "The Cup" is scheduled to be released in Australia in October.

Many women may have a Test of Cervical Cancer every 3 years: study (HealthDay)

Wednesday, may 18 (HealthDay News) - women 30 and older who have good results from each of two cervical cancer tests available today can safely wait three years for their next screening instead just a year, according to new research.

The conclusion is probably not be controversial, said Dr. Charles Capen, Chief of Gynecology/Oncology at Scott & Healthcare White Temple, Texas, given that the most recent guidelines already recommend that women 30 years and more that are otherwise in good health projected with a Pap test and a test for a related virus cancer of the cervix every three years as the first trials are both negative.

Unlike some cancers, cervical cancer is usually slow-growing, and it is curable if detected early, according to the National Cancer Institute of the United States.

"This [new search] confirms the latest directives," agreed Dr. Therese Bevers, Medical Director of the Centre for prevention of Cancer at the University of Texas M.D. Anderson Cancer Center in Houston. "This is fabulous as it may give clinicians and women across a lot of comfort".

This will stimulate also more doctors actually follow these guidelines, we hope, added the Bevers, as recent research has revealed that most doctors are giving most often recommended Pap test - that is to say, once a year.

The results of the study will be presented at the annual meeting of the American Society of Clinical Oncology is held in June in Chicago. The results were published early Wednesday in a teleconference.

The risk of cervical cancer can be assessed by two different tests: the traditional Pap smear test, looking for anomalies of the cervical cells, and a more recent test that can detect the DNA of the virus that causes most cases of cervical cancer : human papillomavirus, or HPV virus. That screening is called the HPV test.

The new study involved more than 330 000 women are enrolled in a health plan in Northern California great who received the two types of tests between 2003 and 2005 and who were followed for five years after the test.

The estimated risk of five years for developing cancer of the cervix was 7.5 per 100,000 women in those who had normal PAP, versus a 3.8 much lower per 100,000 for women who were negative about the HPV test.

When the two trials were conducted with both giving negative results, the estimated risk was 3.2 per 100,000 women, which means that the only HPV test is almost as good as the two combined.

"A single negative HPV test [predicted] risk extremely low cancer for women which was not significantly reduced by having a normal Pap test," lead of said author Hormuzd Katki, principal investigator of the Division of the epidemiology of Cancer and genetics to the U.S. National Cancer Institute.

That means that women who test negative on HPV testing alone may be able to extend their screening intervals to three years without adverse consequences, added Katki.

"It generates the question, the HPV test to become the standard at some point," said Bevers.

This could be particularly important in developing countries who often do not have the ability to interpret Pap test, said Bevers.

"The HPV testing is much easier," she added. "There is little as do a pregnancy test at home." "It is positive or negative".

There is still a role, however, Pap - follow-up of a positive test of the HPV test, said Katki. "The Pap test can identify women who have more immediate disease," he said.

"But many women assimilate a Pap test with their annual pelvic exam and one of the arguments against the screening of three-year intervals is that women would no longer see their doctor every year and obtain other necessary tests.such as pressure artériellecholestérol and screening for sexually transmitted infections "Capen said."

Capen, think however, that won't happen. "Young women may be on the pill or they may be pregnant, hope that they will always get the medical care that they need", he said.

Given that the results of the study must be presented at a medical meeting, they should be considered preliminary until published in a refereed journal.

Colo. woman accused of faking cancer gets prison

GOLDEN, Colorado - a woman suburb of Denver who cheated of the family and friends of nearly $ 60,000 in donations will spend 90 days in prison.

Ann Crall, of Highlands Ranch, was sentenced Thursday in gold. After serving time in prison, she will face 10 years of probation under intensive surveillance of the ruse of false cancer four years which began in 2005.

The authorities say that 31-year-old has deceived her husband, a former police officer, and his colleagues and their church so that she could pay for his habit of prescription drugs.

KMGH-TV in Denver reported that one of the victims of the Crall, J.J. Beattie, was diagnosed with a malignant tumor in the brain itself and Crall asked him for pain medications. Beattie, said that crall is a parody of people who have actually cancer.

Crall apologized in court, calling his actions "folly."

The PSA test earlier Best predicts the risk of dying of Prostate Cancer

Researchers analyzed blood samples 12,090 between 1974 and 1986 Swedish men, whereas they were ages 44 to 50, samples of nearly 5,000 men, six years later, when they were aged 51 to 55 and samples of 1,167 men who were 60.

The men with PSA levels below the median, whereas they were 44-50 had a very low risk of death by cancer of the prostate or metastasis in 15 years. At the age of 60 years, these men with PSA levels below the median, the risk of prostate cancer had significantly decreased to 0.5%.

Although the current American Cancer Society guidelines suggest all but men at high risk should discuss screening with their doctor at the age of 50 years, the study authors say that their results indicate earlier tests could reduce unnecessary testing later.

The results indicate that more than half of men may waive regular PSA Test after this period and were just three tests PSA in their lives, with the first aged 44 to 50, the second between 51 and 55 years, and - if their PSA levels still low is - the third and last 60 years, said researchers at Memorial Sloan - Kettering Cancer Center in New York.

However, men with higher levels of PSA between the ages of 44 and 50 are high aggressive prostate cancer risk and should continue to undergo screening and APS as necessary, researchers have added.

The study to be presented to journalists today 18 may at the annual meeting of the American Society of Clinical Oncology.

"This research helps us to distinguish between men who can benefit from regular PSA for cancer of the prostate and the men who cannot be screening need not so often," lead author Dr. Hans Liljaa clinical chemist with appointments in the departments of medicine, laboratoireChirurgie and medicine, said in a press release of the Memorial Sloan-Kettering.

"Instead of testing all men efforts every year or every two years, screening and surveillance can concentrate on the early detection of cancer of the prostate in men who are considered at high risk of dying from the disease.".

PSA testing is recommended for the early detection of prostate cancer, but is associated with a high rate of over-diagnosis and excessive treatment, which is a concern because the treatment of cancer of the prostate can lead to erectile and urinary problems debilitating.

Because the study is presented at a medical meeting, its results should be considered preliminary until published in a refereed journal.

Smoking raises Odds for Breast Cancer in women at high risk

Researchers have analyzed how smoking, drinking and physical activity affected the risk of several common cancers in the 13,388 women at increased risk of breast cancer due to family history of breast cancer, age and other factors. Women participated in the U.S. National Surgical Adjuvant Breast and bowel (NSABP) Breast Cancer Prevention Trial project.

Those who have never smoked, women who smoke at least 35 years had 60% greater risk of invasive breast cancer and more than four times the risk of colon cancer, the researchers found.

Women who smoke during 15 to 35 years were 34 percent more likely to develop invasive breast cancer and 7 per cent more likely to develop a colon cancer than those who have never smoked.

Smokers to less than 15 years have had no increased risk of invasive breast cancer, according to the report.

To those who have never smoked, women who smoked a pack of cigarettes a day for more than 35 years were 30 times more likely to develop lung cancer, while the risk was 13 times higher for those who have smoked less than a pack a day more than 35 years.

Alcohol consumption was not associated with increased risk of cancer, but researchers have concluded that the low levels of physical activity were associated increased risk of 70% of endometrial cancer. It may be because women are more likely to be obese, a risk factor for endometrial cancer.

The study was posted online before its presentation on 6 June at the annual meeting of the American Society of Clinical Oncology, in Chicago.

"The NSABP study was the first large prospective study to examine the impact of smoking among women at high risk of breast cancer," said study author Stephanie Land, an associate professor of research in the Department of Biostatistics at University of Pittsburgh Graduate School of Public Health.

"Our results show an increase in still more risk that has been shown in previous studies, which suggests that women who are at risk of cancer of the breast of the family history or other factors.", smoking cigarettes is even more risky than other women "Land, said in a release ASCO."

"It sends a very important message for women with a family history of breast cancer on the long-term risks of smoking, and the importance of staying physically active." We note once more that the cessation is one of the most effective tools to reduce the risk of many cancers, ", she added."

Coffee cuts risk of lethal prostate cancer

WASHINGTON - more is better when it comes to drinking coffee to ward off the risk of fatal cancer of the prostate, according to a major study us released by researchers at the Harvard School of Public Health.

Men who drank six cups or more per day had a lower risk of 60 per cent of development the most lethal type of prostate cancer and a lower risk of 20% of training of any type of prostate cancer than men who did not drink coffeeHe said.

Even just one to three cups per day was linked to a lower risk of 30 per cent of lethal cancer of the prostate.

"Few studies have specifically studied the association of intake of coffee and the risk of cancer of the deadly prostate, the form of the disease, which is the most critical to prevent," said Associate Professor of Harvard and principal author Lorelei Mucci.

"Our study is the largest to date whether coffee could reduce the risk of prostate cancer lethal," she said.

The effects are the same if the caffeinated coffee or decaffeinated, leading researchers to believe that the lesser risk may be related to antioxidants and anti-inflammatory benefits of coffee.

Prostate cancer is the most commonly diagnosed form of cancer in men, but it is not always fatal.

A blood test can detect early, and cancer can be noted on what is called a Gleason score; more score more cancer is spreading.

There are 16 million survivors of prostate cancer in the world, and one in six men to the United States will get cancer of the prostate in their lives.

Risk factors are usually linked to Western diet rich in fat, heredity, alcohol and exposure to chemicals.

The study examined men of U.S. 47,911 who reported on how much coffee they drank every four years in 1986 to 2008.

In the course of the study, a total of 5035 prostate cancer cases were reported, including cases fatal, or metastatic, 642.

Lower risk in the drinkers of coffee remains even after authorized researchers for other factors that typically boost risk and were most often observed in that coffee drinkers in abstinent, such as smoking, and failure to exercise.

HPV test beats Pap smear for cervical cancer cervical screening (AP)

By MARILYNN MARCHIONE, AP Medical writer Marilynn Marchione, Ap Medical writer - Wednesday 18 may, 6: 06 pm EST

Two large studies suggest new ways to detect people in good health for cervical cancer or prostate, but a third disappointed those who hope for a way to detect early signs of deadly tumors of the ovary.

The researchers found:

_For women 30 and more, a test for the virus, HPV, is preferable to a PAP test to predict the risk of cervical cancer, and those who test negative on both can safely wait three years to be checked again.

This unique PSA blood test at age 44 to 50 could help predict the risk of a man of advanced cancer of the prostate or dying of it until 30 years later. The PSA test is known to be reliable, but this way he separates men who need close supervision of those who are so low-risk they can ignore testing for five years or more.

_Screening women with no symptoms of cancer of the ovary with a blood test and ultrasound examination is harmful. It did not prevent the death and led to thousands of false alarms, unnecessary surgeries and severe complications.

The latest study is a warning to people who get the tests that are not recommended or that if screening may be ill ever screening.

"The answer is that this could not many, said Mr. Allen Lichter, Director Executive of the American Society of Clinical Oncology." The Group publishes these and 4,000 other studies Wednesday, before its annual meeting, next month.

Cervical cancer is easy to prevent. It is very slow growth and testing research on precancerous cells and allows early treatment. The new study was the first great review most recent screening tool, HPV testing, with or without PAP in current practice.

For a test of PAP, scraped from the cervix, uterine gateway, cells are checked under a microscope. But it may lack problems or raise false alerts.

HPV tests to detect the human papilloma virus, which causes most cases of cervical cancer. But HPV is "cold" regions nil - most of the young sexually active have been exposed to it, said Debbie Saslow, Director of the American Cancer Society for cancer of the breast and gynecological. Most infections go away on their own. they have only a risk of cancer when they last a year or more.

Younger women tend to have infections in the short term, so the Pap test is a better way of their screen. HPV tests are approved option with Paps for women 30 and older, and the cancer society says that if a woman tests negative on both, it can wait three years to be thrown again. Few take this advice, though.

"Their annual Pap and doctors still want to give them want even of women" and is rationing of care test less often, think said Saslow.

The new study gives "very, very strong support" for testing, said Lichter.

Hormuzd Katki of the National Cancer Institute investigated more than 330 000 women cross HPV and Pap tests Kaiser Permanente Northern California for five years.

Year only about three of 100 000 women each developed cancer of the cervix after negative HPV and Pap tests. HPV tests were two times more as good as Paps to predict risk. Adding a Pap after a negative HPV test has little done to improve the prediction of the risk.

However, if an HPV test was positive, a Pap test to confirm or the need for follow-up.

The study did not look at the downside of HPV testing - how many false alarms and unnecessary procedures it triggered. Tests for HPV costs between $80 and $100 compared to $ 20 to $ 40 for Paps.

The study of prostate sought a better way to use the PSA tests, which are troublesome because PSA can be high for many reasons beyond cancer, and doctors don't know that cancers need treatment or whether if screening saves lives. Most groups do recommend APS, but most men over 50 years to do anyway.

The new study "will not put an end to the controversy, but it suggests a very interesting way," Lichter said.

Researchers at Memorial Sloan - Kettering Cancer Center in New York has used blood samples stored 12 000 Swedish men gave for a study of heart for decades, when most were 44 to 50 years. They were also second samples from some of them, six years later and samples of other men in 60 years.

Research 27 years later, scientists have seen that 44% of cancer deaths occurred among men whose initial PSA had been in the top 10 per cent, whereas they were 44 to 50 years.

Conversely, entering below the median means very little risk of cancer years later.

"They're identifying a group of guys who have need to be screened, or must be screened less often,", said Dr. Otis Brawley, Chief Medical Officer of the cancer society.

The results are "provocation", but this type of study cannot prove that screening prevents deaths, said Dr. Matthew r. Smith, Massachusetts General Hospital Cancer Center. Few Swedish men have been treated for prostate cancer, like most men are today, which may affect survival.

The National Cancer Institute, the Swedish society of Cancer and several foundations paid for the work, and a researcher holder of patents for two PSA tests.

Baseline PSA in men in their forties can be recommended even, said Brawley. Cancer society says men should be informed of the risks and benefits of PSA testing starting at age 50 and earlier for blacks and persons with a family history of prostate cancer.

Cancer of the ovary Government-funded study involved nearly 80,000 women. Half was selected every year with a four-year ultrasound and a blood test for six years. The blood test sought to CA-125, une substance often high in ovarian cancer.

After 13 years, there was no major differences in cancers found ovarian or death resulting from the disease. Screening found only 212 cancers while giving the 3,285 false alarms that led to 1,080 unnecessary biopsy surgeries and severe complications 163.

"Many people said ' how the screening be harmful? This thing the documents, "said Brawley.

The results do not apply to the use of these tests on women who have symptoms of cancer of the ovary or abnormal physical examinations. It is still the best way to check for cancer of the ovary in these cases.

___

Online:

CDC on HPV testing: http://www.cdc.gov/hpv/Screening.html

On the HPV cancer society: http://tinyurl.com/44gnadx

Scientific journal of cervical cancer: http://tinyurl.com/6lc2rzg

Oncology Society: www.cancer.net

Viable surgery for advances in Cancer of the Prostate study finds (HealthDay)

surgery to remove the prostate (radical prostatectomy) leads to a survival rate of 20 to 80 per cent of patients with advanced prostate cancer, a new study concludes.

The study involved patients with cancer that has spread beyond the prostate, known as the cT3 prostate cancer and has undergone a radical prostatectomy between 1987 and 1997.

Survival of 80 per cent of these patients is comparable to a survival rate of 90% at 20 years for patients with cancer confined to the prostate (cancer of the prostate cT2), said Mayo Clinic researchers.

Previously, the authors of the study of patients with cancer of the prostate cT3 were offered to strike out or hormone therapy, but not radical prostatectomy, noted in a press release of Mayo.

"We're a much better job of identifying and expansion of the candidates for the surgery, which translates into longer, better results for both of our patients," Dr. r. Jeffrey Karnes, urology department, said in the press release.

The study was scheduled for the presentation of May 15 at the annual meeting of the American Urological Association, Washington, D.C. presented research at meetings is considered preliminary until published in a refereed journal.